Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-573 + cyclophosphamide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
TAK-573 + cyclophosphamide + dexamethasone is an experimental combination regimen under investigation for the treatment of relapsed/refractory multiple myeloma (RRMM). TAK-573 (modakafusp alfa) is a first-in-class immunocytokine designed to deliver attenuated interferon alpha-2b to CD38-positive cells, resulting in both direct cytotoxic activity and immune system modulation. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death, and dexamethasone is a synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects and is commonly used in myeloma regimens. The combination is in clinical evaluation for multiple myeloma, though most available studies focus on TAK-573 alone or in combination with dexamethasone and not routinely with cyclophosphamide. The mechanism of action for the combination is presumed to include targeted immunotherapy, cytotoxic chemotherapy, and immunosuppression.
- Other names
- modakafusp alfa + cyclophosphamide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)DNA
Beyond the preview
Go deeper on TAK-573 + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-573 + cyclophosphamide + dexamethasone.